$23.85
1.85% yesterday
Nasdaq, Nov 14, 10:11 pm CET
ISIN
US1421521071
Symbol
CAI

Caris Life Sciences Stock price

$23.85
-6.51 21.44% 1M
+2.85 13.57% 6M
+2.85 13.57% YTD
+2.85 13.57% 1Y
+2.85 13.57% 3Y
+2.85 13.57% 5Y
+2.85 13.57% 10Y
+2.85 13.57% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
-0.45 1.85%
ISIN
US1421521071
Symbol
CAI

Key metrics

Basic
Market capitalization
$6.7b
Enterprise Value
$6.4b
Net debt
positive
Cash
$721.2m
Shares outstanding
281.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.4 | 9.9
EV/Sales
8.9 | 9.4
EV/FCF
negative
P/B
14.9
Financial Health
Equity Ratio
-80.6%
Return on Equity
136.5%
ROCE
-38.5%
ROIC
-167.0%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$714.6m | $678.8m
EBITDA
$-288.4m | $-13.0m
EBIT
$-333.1m | $-94.2m
Net Income
$-1.0b | $-717.9m
Free Cash Flow
$-206.1m
Growth (TTM | estimate)
Revenue
- | 64.7%
EBITDA
- | 94.9%
EBIT
- | 63.4%
Net Income
- | -89.8%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
49.2%
EBITDA
-40.4% | -1.9%
EBIT
-46.6%
Net
-143.1% | -105.8%
Free Cash Flow
-28.8%
More
EPS
$-3.6
FCF per Share
$-0.7
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Caris Life Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Caris Life Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Caris Life Sciences forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Caris Life Sciences forecast:

Buy
92%
Hold
8%

Financial data from Caris Life Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
715 715
-
100%
- Direct Costs 363 363
-
51%
351 351
-
49%
- Selling and Administrative Expenses 522 522
-
73%
- Research and Development Expense 162 162
-
23%
-288 -288
-
-40%
- Depreciation and Amortization 45 45
-
6%
EBIT (Operating Income) EBIT -333 -333
-
-47%
Net Profit -1,023 -1,023
-
-143%

In millions USD.

Don't miss a Thing! We will send you all news about Caris Life Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caris Life Sciences Stock News

Neutral
Seeking Alpha
10 days ago
Caris Life Sciences, Inc. ( CAI ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants J. Denton - Senior VP, General Counsel & Secretary David Halbert - Chairman, CEO & Founder Brian Brille - Executive Vice Chairman & Executive VP David Spetzler - President Luke Power - Senior VP, CFO & Chief Accounting Officer Conference Call Participants Vijay Kumar - Evercore ISI Institut...
Neutral
PRNewsWire
10 days ago
Revenue growth of 113% driven by strong performance in molecular profiling services Raises 2025 revenue guidance to $720 to $730 million, representing year-over-year growth of 75-77% IRVING, Texas , Nov. 5, 2025 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended September...
Neutral
PRNewsWire
17 days ago
IRVING, Texas , Oct. 29, 2025 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors. The study titled...
More Caris Life Sciences News

Company Profile

Caris Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Irving, Texas. The company went IPO on 2025-06-18. Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Head office United States
Website www.carislifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today